Evotec SE stock rebounds 5.75% on Xetra amid biotech volatility and partnership progress

Evotec SE (ISIN: DE0005664809) shares climbed 5.75% to 4.356 EUR on Xetra, signaling potential stabilization after recent preliminary 2025 results miss and pipeline setbacks. US investors should watch key collaborations with Bristol Myers Squibb and AI-driven initiatives for turnaround potential in this German drug discovery leader.

Evotec SE stock surged 5.75% to 4.356 EUR on Xetra, reflecting renewed investor interest in the German biotech's partnerships and AI advancements amid sector-wide volatility. The rebound follows a sharp selloff triggered by preliminary 2025 results released on March 18, 2026, which showed revenue of approximately €820 million, up 5% year-over-year but below expectations of €850 million. Delayed milestones and widened EBIT losses to €150 million fueled concerns, yet recent updates on Bristol Myers Squibb collaborations offer hope. For US investors, Evotec's ties to major pharma players like BMS and Bayer provide exposure to small-molecule discovery without direct biotech development risks.

As of: 26.03.2026

Dr. Marcus Hale, European Biotech Analyst: Evotec SE's integrated platform and Big Pharma partnerships position it as a resilient play in drug discovery, especially as AI tools accelerate timelines in a funding-tight environment.

Recent Financial Update Sparks Initial Selloff but Quick Recovery

Evotec SE released preliminary full-year 2025 figures on March 18, 2026, reporting group revenue of about €820 million, a 5% increase from 2024 but short of the €850 million consensus. The shortfall arose from postponed milestones in partnerships and softer fee-for-service billing in the services unit. EBIT losses expanded to €150 million, attributed to elevated R&D investments in proprietary programs and AI infrastructure.

Management projected 2026 revenue between €850-900 million, suggesting modest growth, while warning of €200 million cash burn linked to AI discovery enhancements. The Evotec SE stock dropped 12% to €8.20 on Xetra in EUR over the next two days post-release, hitting a 52-week low amid broader biotech funding worries. However, by March 25, 2026, shares on Xetra recovered sharply, up 6.39% intraday and closing at 4.356 EUR with a +5.75% gain, as noted in market updates.

This volatility underscores investor sensitivity to execution in contract research organizations (CROs), where Evotec operates. The €9 billion order backlog provides revenue visibility, but near-term milestone delays worth €100 million highlight dependency on partner progress.

Core Business Model: Partnerships Drive Revenue Amid Challenges

Evotec SE functions as an integrated drug discovery provider, collaborating with pharmaceutical giants on small-molecule programs while nurturing its own pipeline in fibrosis, oncology, and infectious diseases. In 2025, partnerships generated 65% of revenue through milestones and royalties from deals with Bristol Myers Squibb, Bayer, and Sanofi.

The model hinges on clinical advancements, which faltered last year with two Phase II trials missing endpoints, deferring €100 million in payments. Cash reserves ended 2025 at €350 million, offering an 18-month runway, though further dilution risks persist if new deals lag. Year-to-date, the Evotec SE stock has declined 40% on Xetra in EUR, underperforming the MDAX by 25 points.

Evotec's fee-for-service and alliance structures differentiate it from pure-play biotechs, providing steadier cash flows. Its focus on high-unmet-need areas like neuroscience and immunology aligns with Big Pharma priorities, potentially buffering sector downturns.

Pipeline Highlights: BMS Oncology Advance Fuels Optimism

Evotec's proprietary pipeline includes EVT201 for Alzheimer's, advancing to Phase II on positive Phase I results, and EVO271 targeting Parkinson's disease. Partnerships dominate, with 18 molecules in clinical stages from collaborations. A key March 20, 2026, announcement confirmed a BMS-partnered oncology asset moving to Phase III, potentially unlocking €300 million in milestones.

On March 23, 2026, Evotec's unit was selected to optimize manufacturing for an antibody cocktail, adding to positive momentum. These developments contrast recent setbacks, where pipeline delays contributed to the 2025 revenue miss. The company's therapeutic focus spans CNS insomnia, chronic cough, immunology, women's health, nephrology, dermatology, fibrosis, and antivirals.

Progress in partnered assets like the BMS program validates Evotec's discovery engine, critical for regaining investor confidence. Success here could accelerate milestone inflows, easing cash burn pressures.

AI Integration and Strategic Moves Position for Growth

Evotec launched EVOlearn in 2025, an AI platform slashing hit identification times by 30%, drawing interest from Eli Lilly. Planned 2026 capex of €50 million will expand this capability. To counter costs, the firm cut headcount by 10%, targeting €40 million in savings.

These initiatives address core challenges in biotech discovery: speed and efficiency. Peers like Lonza boast stronger margins, but Evotec's AI push could narrow the gap, enhancing competitiveness in small-molecule space. The €9 billion backlog underscores long-term demand for its services.

Management's focus on AI aligns with industry trends, where hyperscalers and pharma invest heavily in computational biology. Early EVOlearn results suggest tangible benefits, potentially boosting win rates on new partnerships.

Why US Investors Should Monitor Evotec SE Now

US investors gain indirect exposure to Evotec's innovations via partnerships with American giants like Bristol Myers Squibb and Eli Lilly, who rely on its discovery platform for pipeline replenishment. With 18 clinical-stage assets from collaborations, successes directly benefit Evotec through milestones and royalties.

The recent Xetra rebound to 4.356 EUR (+5.75%) on March 25, 2026, coincides with SDAX strength, where Evotec led gainers at +6.39% intraday. Valuation metrics show 2025 P/E at -11.6x and EV/Sales at 0.97x, suggesting undervaluation if growth accelerates. Market cap stands at 772M EUR on Xetra.

In a biotech landscape marked by volatility, Evotec's CRO-like model offers downside protection via service revenues. US portfolios diversified into European small-caps could benefit from its AI edge and Big Pharma ties, especially as FDA approvals loom for partnered drugs.

Key Risks and Open Questions Ahead

Persistent losses and €200 million 2026 cash burn raise dilution specters if milestones falter. Pipeline risks remain, with proprietary programs like EVT201 facing Phase II hurdles common in neuroscience. Sector funding constraints could slow new deals, pressuring the €350 million cash pile.

Competition from larger CROs like Lonza intensifies, demanding flawless AI execution. Regulatory delays in partnered trials, particularly the BMS oncology asset, could defer €300 million inflows. Broader biotech sentiment, tied to interest rates and M&A, adds uncertainty.

Investors must weigh the €9 billion backlog's durability against execution gaps. While recent rebounds signal optimism, sustained profitability hinges on milestone realizations and cost controls.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.